John Brendan Doyle
Known title: Chief Financial OfficerCIK: 0001840738
John Brendan Doyle's purchase track record
John Brendan Doyle has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/16/2026 | CGTX | $11K | -15.3% | -34.0% | +10.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CGTX | ▼ Sell | Tax Withholding | 8,567 | $11K | 5/1/2026 | View on chart |
| CGTX | ▲ Buy | Open Market | 10,000 | $11K | 4/16/2026 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 1,560 | $2K | 2/15/2026 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 26,921 | $28K | 2/4/2026 | View on chart |
| CGTX | ▲ Buy | Grant | 200,000 | $0 | 2/3/2026 | View on chart |
| CGTX | ▲ Buy | Grant | 30,000 | $0 | 12/18/2025 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 9,360 | $14K | 12/18/2025 | View on chart |
| CGTX | ▲ Buy | Grant | 30,000 | $0 | 7/29/2025 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 9,360 | $6K | 7/29/2025 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 9,692 | $4K | 5/1/2025 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 1,723 | $1K | 2/15/2025 | View on chart |
| CGTX | ▲ Buy | Grant | 295,000 | $0 | 2/4/2025 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 8,699 | $17K | 5/1/2024 | View on chart |
| CGTX | ▲ Buy | Grant | 20,000 | $0 | 2/15/2024 | View on chart |
| CGTX | ▲ Buy | Grant | 109,824 | $0 | 5/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20
Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20. Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.